Pacira BioSciences
PCRX
210 hedge funds and large institutions have $1.57B invested in Pacira BioSciences in 2019 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 77 increasing their positions, 63 reducing their positions, and 34 closing their positions.
81% more call options, than puts
Call options by funds: $9.45M | Put options by funds: $5.23M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
22% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 63
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
2.23% more ownership
Funds ownership: 98.02% → 100.25% (+2.2%)
1% more funds holding
Funds holding: 208 → 210 (+2)
7% less capital invested
Capital invested by funds: $1.69B → $1.57B (-$115M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$53.8M |
| 2 |
AC
Armistice Capital
New York
|
+$41.8M |
| 3 |
Renaissance Technologies
New York
|
+$27.6M |
| 4 |
D.E. Shaw & Co
New York
|
+$22.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$69.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$25.8M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$12.9M |
| 5 |
DCM
Daruma Capital Management
New York
|
-$11M |
PCRX Hedge Fund Activity: Q1 2019 in Review
210 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2019, worth a combined $1.57B — down 6.8% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PCRX positions and 34 closed out — a net gain of 4 holders — while 77 added to existing stakes and 63 trimmed.
The largest buyer was Frontier Capital Management, opening a new position worth an estimated $53.8M. The largest seller was HealthCor Management, cutting an estimated $69.9M.
- 210 institutional investors held Pacira BioSciences (PCRX) as of Q1 2019, up from 208 in Q4 2018.
- Funds reported $1.57B of Pacira BioSciences stock for Q1 2019, down 6.8% quarter-over-quarter.
- 38 funds opened new Pacira BioSciences positions in Q1 2019 and 34 closed out, a net change of +4 holders.
- The largest Pacira BioSciences buyer in Q1 2019 was Frontier Capital Management, an estimated $53.8M added.
- The largest Pacira BioSciences seller in Q1 2019 was HealthCor Management, an estimated $69.9M sold.
Based on aggregated 13F filings for Q1 2019.